Don’t miss our top 5 cancer-related stories this month, including a guest commentary from an industry leader, our two-part series on trends in cancer research and more!
 
Revolutionizing and personalizing global health 
By E. Kevin Hrusovsky, PerkinElmer Inc.
As the complexity and volume of data continue to rise, bioinformatics is emerging as one of the cornerstones of personalized medicine, from enabling discovery and development of novel treatments and diagnostics to facilitating collection, analysis and interpretation of data that ultimately helps an individual patient.  

SPECIAL REPORT PART 1: ‘Good enough’ is no longer good enough 
By Randall Willis, ddn Features Editor
Aiming beyond the standard of care in oncology  

SPECIAL REPORT PART 2: An aside on side effects 
By Randall Willis, ddn Features Editor
Are we really making things better for cancer patients?  

High-profile oncology partnership
By Jim Cirigliano, ddn Contributing Editor
Araxes Pharma and Janssen Biotech ink oncology drug development deal  

Natural neighbors 
By Kelsey Kaustinen, ddn Features Editor
OSU, Biosortia link up to identify natural products for potential cancer treatments  

 
PerkinElmer
 
 
Ventana, Bayer collaborate on ADC diagnostic test
March 2012
SHARING OPTIONS:

TUSCON, Ariz.—Ventana Medical Systems Inc. and Bayer Pharma AG have joined forces to develop a molecular companion diagnostic test to identify patients that are most likely to benefit from Bayer’s antibody-drug conjugate, or ADC, cancer therapy. Per the agreement, Ventana will use its technology to analyze expression levels in certain tumor targets serving as biomarkers in clinical studies and will be responsible for developing, manufacturing and commercializing a test for one of Bayer’s ADC drugs. For up to five years, either company can initiate further projects to develop diagnostic tests for additional cancer therapy drugs. Financial terms were not disclosed.
 
“As new biomarkers and diagnostic tests become increasingly available, they provide valuable information about potential positive recipients for these novel agents,” Mara Aspinall, president of Ventana, said in a press release.

Back

Asuragen


Charles River Labs

Waters

Tecan

Eppendorf
CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
Cisbio
© Copyright 2013 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.